Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis
Status:
Completed
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
Denosumab is an antibody against receptor-activator of nuclear factor kappa-B ligand that
prevents recruitment and differentiation of mature osteoclasts. Treatment markedly decrease
bone resorption and fracture risk, and many patients will reach osteopenic bone mineral
density (BMD) levels on treatment with denosumab. The treatment effect on bone turnover and
BMD has, however, been demonstrated to be reversible. This study will show if the bone mass
can be maintained by administrating zoledronic acid and if timing of the first dose of
zoledronic acid after last dose of denosumab matters.